Personalized neoantigen vaccine in ovarian cancer, phase 1: feasible, with escape pointing to antigen presentation
NeoVax after standard chemotherapy was feasible in first relapse (9/12) and induced T-cell responses in 8 of 10 patients; progression tracked with HLA loss and JAK1 alterations.





















